B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653" (PORF)
Euronext Amsterdam · Netherlands · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 13.50 |
|---|---|
| 52-week range | 11.30 – 14.80 |
| Return, 1 month / 3 months | −3.6% / +8.0% |
| Return, 1 year / 3 years | +18.2% / +19.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 27 |
| Volatility (1 year) | 37.7% |
| Worst drawdown (1 year) | -16.2% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | 4.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
B.V. Delftsch Aardewerkfabriek De Porceleyne Fles, commonly known as Royal Delft, is a Dutch ceramics maker based in Delft. It produces hand-painted earthenware and porcelain, chiefly the blue-and-white decorated pottery known as Delftware, including plates, vases, tiles and ornamental pieces. Its customers include collectors, visitors and gift buyers, and the company also runs a museum and workshop where the painting craft is shown to the public.
The shares are listed on the Euronext Amsterdam in Netherlands under the code PORF, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653" (PORF) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 13.50 on 21 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 58 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 18.2% and over the last three months it rose 8.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.1% | ||
| From 52-week high | -8.8% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.0% | ||
| 6-month return | -2.3% | ||
| 12-month return, skipping the last month | 22.6% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 37.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.2% | ||
| Liquidity | 4 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 41.7% | ||
| Income | 37 · Weak | Dividend is small or irregular. | |
| Dividend yield | 4.4% | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −6.3% |
|---|---|
| 1 month | −3.6% |
| 3 months | +8.0% |
| 6 months | −2.3% |
| 1 year | +18.2% |
| 3 years | +19.4% |
| 5 years | +51.0% |
Signals
| 50-day / 200-day average | 13.83 / 13.09 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.15 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 0.6000 |
| 15 May 2025 | EUR 0.5500 |
| 16 May 2024 | EUR 0.5736 |
| 23 May 2019 | EUR 0.5215 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.